The myth that people with dark skin are immune to melanoma, a type of skin cancer, has persisted for many years. It's a dangerous misconception that has caused some people not to be diligent about protecting themselves against ...
May 12, 2023
0
3
For many people, playing and relaxing in the sun is fun. But for skin cancer survivors, the sun can be a source of fear and anxiety. That's because sun exposure is one of the most significant risk factors for developing skin ...
May 11, 2023
0
2
A tiny spot on Christy Staats's cheek measured just 0.65 millimeters—or 0.025 inches—and was almost invisible to the human eye. But with help from state-of-the-art non-invasive technology, an OHSU dermatologist and a ...
May 1, 2023
0
4
In a new translational study from UCLA Jonsson Comprehensive Cancer Center, researchers analyzed genetic changes in the organs of recently deceased patients to understand how metastatic cutaneous melanoma spreads in those ...
Apr 27, 2023
0
30
Researchers from Harvard's Stem Cell and Regenerative Biology (HSCRB)'s Zon lab have discovered a new mechanism that influences melanoma development, a finding that could have wide implications for patients across a variety ...
Apr 27, 2023
0
175
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
Apr 25, 2023
0
72
It's only April, but many people across the country and the globe are already enjoying summerlike temperatures. But getting out in the sun also increases your risk of getting skin cancer.
Apr 21, 2023
0
3
Cutaneous melanoma, the most aggressive form of skin cancer, is the fifth most diagnosed cancer in Europe and one of the most frequent causes of cancer death, with incidence and mortality trends on the rise. While the development ...
Apr 20, 2023
0
2
Clinical eligibility guidelines determine the criteria by which patients are selected for various medical procedures. But strict reliance on established guidelines can overlook patients who might benefit from a procedure, ...
Apr 19, 2023
0
6
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination ...
Apr 17, 2023
0
2
